Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

The peptide structure of Tirzepatide includes modifications that are believed to increase its stability and extend its activity, potentially leading to more sustained metabolic impacts.

Tirzepatide is a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it a unique peptide with multifaceted impacts on metabolic regulation.

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes ... Pfizer, Regeneron, Rhythm Pharmaceuticals, Scholar Rock, Structure Therapeutics, Terns ...

Taking tirzepatide reduced the risk of progressing to diabetes by 93% (HR 0.07, P<0.001) compared to placebo over 3 years, with only 1.3% of participants on tirzepatide developing diabetes ...

A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand named Zepbound, included ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached (Fig. S1 in the ...

The efficacy estimand results demonstrated treatment with tirzepatide 5mg, 10mg, and 15mg led to average weight reductions of 15.4%, 19.9%, and 22.9%, respectively, compared with 2.1% for placebo.